Introduction Ropivacaine belongs to pipecoloxylidide group of local anesthetics. There are reports supporting the use of ropivacaine as a long acting local anesthetic in oral and maxillofacial surgical procedures, with variable data on the concentration that is clinically suitable. Materials and Methods A prospective randomized double-blind study protocol was undertaken to assess the efficacy of 0.5 and 0.75 % ropivacaine for inferior alveolar nerve block in surgical extraction of impacted mandibular third molars. A total of 60 procedures were performed, of which thirty patients received 0.5 % and thirty received 0.75 % concentration of the study drug.
Introduction
Ropivacaine is a newer amide long-acting local anesthetic with chemical similarity to bupivacaine and mepivacaine [1] . Ropivacaine belongs to pipecoloxylidide group of local anesthetics [2] . Chemically ropivacaine is the monohydrate of the hydrochloride salt of 1-propyl-2 0 ,6 0 -pipecoloxylidide. Ropivacaine is available as an enantiomerically pure form (S-enantiomer), contrasting to bupivacaine which is a racemic mixture of (R)-and (S)-enantiomers [1, 3] . There are reports supporting the use of ropivacaine as a long acting local anesthetic in oral and maxillofacial surgical procedures requiring surgical anaesthesia and post-operative analgesia [4, 5] . El-Sharrawy and Yagiela in their scientific report assessed the anesthetic efficacy of different ropivacaine concentrations for inferior alveolar nerve block D. Bhargava Department of Oral and Maxillofacial Surgery, Peoples College of Dental Sciences and Research Center, Peoples University, Bhanpur, Bhopal, MP, India and found that 0.5 and 0.75 % concentrations of the drug were sufficient to produce anesthesia for exodontia [6] . In a similar dose finding study from Institute of Odontology, Karolinska Institute, Sweden, only ropivacaine at 7.5 mg/mL (0.75 %) produced sufficient pulpal anesthesia when used for mandibular nerve blocks [4] . As benefits of ropivacaine are maximal in surgical procedures requiring long post-operative analgesia, the presented study analysis the anesthetic efficacy of 0.5 and 0.75 % ropivacaine for inferior alveolar nerve block in surgical removal of impacted mandibular third molars.
Materials and Methods
A prospective randomized double-blind study protocol was designed to assess the efficacy of 0.5 and 0.75 % ropivacaine for inferior alveolar nerve block in surgical extraction of impacted mandibular third molars. A total of 60 patients were enrolled for the study. Inclusion criteria for this prospective study were American Society of Anesthesiologists (ASA) Class I subjects over 18 years of age with asymptomatic impacted class II position B mesioangular mandibular third molars. All the patients included for this study were elective candidates for transalveolar extraction of mandibular third molar who gave a written informed consent for the study. The subjects were randomly allocated into 2 study groups for receiving 0.5 and 0.75 % ropivacaine anesthetic solution by lot system. Neither the patient nor the operating surgeon was aware of the concentration of the anesthetic solution. The 1.8 mL anesthetic solution was administered for inferior alveolar nerve block using EO sterilized disposable luer lock type syringe fitted with 0.45 9 38 mm needle (26 gauge, Unolok, India). Each concentration of 0.5 % (Themis Medicare Ltd, India) and 0.75 % (Neon Laboratories Ltd, India) ropivacaine was administered in 30 patients. The same clinician performed all inferior alveolar nerve block injections using an aspirating technique in a standard manner [7] . The onset of mandibular anesthesia was assessed by the subjective signs of lower lip and partial tongue numbness, and was confirmed objectively using a moons probe. The parameters recorded were: time of onset (time from needle withdrawal to the onset of subjective signs), pain during flap reflection, pain during bone guttering, pain during tooth elevation/ sectioning and the duration of the soft tissue anesthesia (loss of lower lip numbness). A 10-point visual analog scale (VAS) was used to subjectively assess the pain scores where point 1 on the VAS indicated minimal discomfort and 10 indicated unbearable pain. Any patient eliciting a VAS pain score of 3 or more during the initial probing to check objective symptoms of anesthetic efficacy or during any stage of the surgical procedure was administered a rescue inferior alveolar nerve block using 1.8 mL 2 % lignocaine with 1:200,000 epinephrine and the need to reanesthetize the surgical site was recorded. Surgical access to the third molar was achieved with a modified ward's mucoperiosteal flap and bone removal with a 702 surgical carbide fissure bur (SS White, Lakewood, NJ) on straight surgical micro-motor/hand piece with a normal saline irrigation. All the study parameters were also recorded by the operator who was blinded for the study drug concentrations. Data was processed using College of Saint Benedict and Saint John's University statistical calculators and XL toolbox Ver 2.81 [8] .
Results
Sixty patients were included in this study, of which 37 were males and 23 were females. The average age of the study patients was 30.0 ± 7.41 years (range: 18-42 years). The time of onset considered was from the withdrawal of the needle after injection of local anesthetic to subjective symptoms of lower lip and tongue numbness. Time of onset was longer for 0.5 % ropivacaine when compared to 0.75 % solution (Table 1, Figs. 1 and 2 ). All the patients in both the study groups reported subjective numbness of lip and tongue. 93.3 % of the study patients in 0.5 % ropivacaine group reported pain corresponding to VAS C3 during bone guttering and VAS [4 during tooth elevation. None of the patients in 0.75 % ropivacaine group reported VAS [3 at any stage of the surgical procedure. All the patients who reported VAS scores of C3 in 0.5 % ropivacaine group were administered rescue lignocaine inferior alveolar nerve block. 0.5 % ropivacaine group was excluded in recording the duration of anaesthesia (soft tissue) expected with the use of ropivacaine as an anaesthetic in such procedures when administered via inferior alveolar nerve block, as 93.3 % study sample was administered rescue lignocaine block. The duration of soft tissue anesthesia recorded with 0.75 % ropivacaine was average 287.57 ± 42.0 min for 30 patients in 0.75 % ropivacaine group (Hi = 405.0; Low = 225.0; Median = 280.0) (Fig. 3) . The average VAS recordings for 0.75 % ropivacaine group was 2.07 ± 0.640. No local or systemic adverse effects were reported with the volume of drug used in all the study patients of this trial. 
Discussion
Ropivacaine is a well tolerated long acting regional anaesthetic with a safer clinical profile. It has a wide array of clinical advantages over currently used bupivicaine as a long acting local aesthetic agent, (summarized in Tables 2  and 3 ) [2] . Ropivicaine concentration that should be considered for dental nerve blocks remains investigational with some reports proving efficacy of 0.5 % solutions for inferior nerve blocks [6] . A dose finding study by Ernberg and Kopp disapproved the use of concentrations less than 7.5 mg/mL (0.75 %) to achieve clinically sufficient pulpal anaesthesia [4] . Our results had similar findings with only 0.75 % ropivacaine solution providing sufficient anaesthesia for bone guttering and tooth elevation, although 0.5 % ropivacaine elicited both lip and tongue numbness. In this study, the latency recorded from the injection to onset of lip and tongue numbness was significantly more for 0.5 % ropivacaine. Onset for 0.75 % concentration group was 120.57 ± 38.4 s when compared to 395.87 ± 67.5 s for 0.5 % ropivacaine. The duration of surgical procedure was similar for both the study groups (statistically insignificant difference). The study assessed duration of soft tissue anaesthesia only in the 0.75 % ropivacaine group. Rescue blocks of lignocaine had to be administered in more than 90 % study patients in 0.5 % ropivacaine group as they complained of pain during various steps of the surgical procedure. Mucoperiosteal flap reflection had comparable VAS scores for both the study groups, with radical increase in pain scores (VAS) during bone guttering with a rotary instrument in 0.5 % ropivacaine group. The long duration of anesthesia achieved with 0.75 % ropivacaine (average 287.57 ± 42.0 min) was advantageous for elevating pain in immediate post-operative period. The minimum to maximum duration of soft tissue anaesthesia recorded in this study was from a minimum of 225.0 min to a maximum of 405.0 min. With safer cardiovascular and central nervous system toxicity profile, longer duration of anesthesia, selective action on the pain-transmitting Ad and C nerves and Table 2 Ropivacaine verses bupivicaine Clinical advantages ropivacaine offers over currently used bupivicaine 1. Ropivacaine is less lipophilic than bupivacaine, with less penetration in large myelinated motor fibres. Clinically, it has selective action on the pain-transmitting Ad and C nerves rather than Ab fibres (motor nerves)
2. The reduced lipophilicity is also associated with decreased potential for central nervous system toxicity and cardiotoxicity. vasoconstriction properties [9] , 0.75 % ropivacaine is a good addition to the list of long acting local anaesthetics for use in oral and maxillofacial surgical practice.
